COMMUNIQUÉS West-GlobeNewswire

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

29/05/2024 - 22:05

BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small [...]

Immuneering to Present at the Jefferies Global Healthcare Conference

29/05/2024 - 22:05

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of [...]

Cardiff Oncology to Present at the Jefferies Healthcare Conference

29/05/2024 - 22:05

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced [...]

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

29/05/2024 - 22:05

SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]

QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine

29/05/2024 - 22:05

QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and [...]

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

29/05/2024 - 22:05

TAMPA, FL, May 29, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. ( Nasdaq: MEDS ) (the “Company”), announced that, on May 23, 2024, the Company received a notice (the “Notice”) from the Nasdaq Listing Qualifications [...]

Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference

29/05/2024 - 22:05

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]

OneMedNet Inks Agreement with a Global Top-10 Medical Technology Company

29/05/2024 - 22:05

OneMedNet’s new iRWD™ platform customer impacts more than 150 million patients each year MINNEAPOLIS, May 29, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading [...]

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

29/05/2024 - 22:01

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of [...]

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

29/05/2024 - 22:01

- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and [...]

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

29/05/2024 - 22:01

BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of [...]

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

29/05/2024 - 22:01

Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic [...]

Cytokinetics to Participate in June Investor Conferences

29/05/2024 - 22:00

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in June: [...]

Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference

29/05/2024 - 22:00

EMERYVILLE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive [...]

Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference

29/05/2024 - 21:30

Innovative cell therapy manufacturing platform moving industry toward widespread patient access to life-saving cell and gene therapies LONDON, May 29, 2024 (GLOBE NEWSWIRE) -- Ori Biotech Ltd. (Ori), a leader in cell [...]

InnovAge Celebrates Grand Opening of Orlando’s First PACE Center in Partnership with Orlando Health

29/05/2024 - 19:05

PACE Program Provides Highly Coordinated, Personalized Senior Care ORLANDO, Fla., May 29, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive [...]

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

29/05/2024 - 18:02

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 29 May, 2024, 6pm CET AB Science SA (Euronext [...]

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA

29/05/2024 - 18:02

COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE D'AUTORISATION CONDITIONNELLE DE MISE SUR LE MARCHÉ DU MASITINIB DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE Paris, 29 mai 2024, 18h AB Science [...]

Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 19 juin 2024

29/05/2024 - 18:00

Mise à disposition des documents préparatoires à l’Assemblée générale mixte du 19 juin 2024 Nantes, le 29 mai 2024, 18 heures – OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnémo: OSE) annonce la mise en ligne des [...]